Memory falls on acute mania data

MEMY fell $1.12 (36%) to $2.01 on 1.7 million shares on Monday after MEM 1003 missed the primary and secondary endpoints in a Phase IIa trial to treat acute mania in bipolar disorder. In the double-bl...